ATXN2 and Machado-Joseph disease: Taking advantage of the large and deeply phenotyped ESMI cohort, we contribute to a more precise understanding of the influence of the intermediate CAG repeat of ATXN2 on SCA3, especially disease progression and non-ataxic symptoms.